Aperio Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $67.9M | Sell |
679,527
-35,482
| -5% | -$3.76M | 0.2% | 79 |
|
|
2020
Q3 | $78.4M | Buy |
715,009
+9,714
| +1% | +$1.08M | 0.26% | 62 |
|
|
2020
Q2 | $74.6M | Buy |
705,295
+16,854
| +2% | +$1.74M | 0.28% | 61 |
|
|
2020
Q1 | $61.5M | Buy |
688,441
+57,076
| +9% | +$5.37M | 0.27% | 65 |
|
|
2019
Q4 | $63M | Buy |
631,365
+18,093
| +3% | +$1.7M | 0.23% | 83 |
|
|
2019
Q3 | $54.7M | Buy |
613,272
+69,091
| +13% | +$5.99M | 0.22% | 88 |
|
|
2019
Q2 | $44.9M | Sell |
544,181
-727
| -0.1% | -$57K | 0.18% | 114 |
|
|
2019
Q1 | $44.1M | Buy |
544,908
+10,761
| +2% | +$848K | 0.19% | 109 |
|
|
2018
Q4 | $40.6M | Buy |
534,147
+29,490
| +6% | +$2.3M | 0.2% | 102 |
|
|
2018
Q3 | $39.9M | Buy |
504,657
+21,770
| +5% | +$1.65M | 0.18% | 126 |
|
|
2018
Q2 | $33.9M | Buy |
482,887
+30,595
| +7% | +$2.2M | 0.16% | 142 |
|
|
2018
Q1 | $31.6M | Buy |
452,292
+43,997
| +11% | +$3.05M | 0.16% | 148 |
|
|
2017
Q4 | $28.3M | Buy |
408,295
+41,415
| +11% | +$2.79M | 0.14% | 166 |
|
|
2017
Q3 | $24.9M | Buy |
366,880
+2,862
| +0.8% | +$181K | 0.14% | 169 |
|
|
2017
Q2 | $24.8M | Buy |
364,018
+41,752
| +13% | +$2.73M | 0.15% | 154 |
|
|
2017
Q1 | $20.1M | Buy |
322,266
+8,067
| +3% | +$470K | 0.14% | 177 |
|
|
2016
Q4 | $17.2M | Sell |
314,199
-238,696
| -43% | -$13.6M | 0.13% | 176 |
|
|
2016
Q3 | $36.3M | Buy |
552,895
+23,270
| +4% | +$1.52M | 0.26% | 82 |
|
|
2016
Q2 | $32M | Buy |
529,625
+1,726
| +0.3% | +$100K | 0.25% | 91 |
|
|
2016
Q1 | $29.7M | Sell |
527,899
-69,206
| -12% | -$4.16M | 0.25% | 86 |
|
|
2015
Q4 | $40.5M | Buy |
597,105
+69,144
| +13% | +$4.53M | 0.37% | 53 |
|
|
2015
Q3 | $33.6M | Buy |
527,961
+57,249
| +12% | +$3.77M | 0.34% | 56 |
|
|
2015
Q2 | $30M | Buy |
470,712
+23,910
| +5% | +$1.64M | 0.31% | 69 |
|
|
2015
Q1 | $30.6M | Buy |
446,802
+51,640
| +13% | +$3.59M | 0.34% | 60 |
|
|
2014
Q4 | $27.8M | Sell |
395,162
-21,155
| -5% | -$1.51M | 0.34% | 54 |
|
|
2014
Q3 | $29.7M | Buy |
416,317
+15,412
| +4% | +$1.13M | 0.4% | 44 |
|
|
2014
Q2 | $29.8M | Sell |
400,905
-4,864
| -1% | -$352K | 0.43% | 38 |
|
|
2014
Q1 | $26.3M | Buy |
+405,769
| New | +$26.2M | 0.37% | 41 |
|
|
2013
Q4 | – | Sell |
-323,078
| Closed | -$17.6M | – | 50 |
|
|
2013
Q3 | $16.8M | Buy |
323,078
+53,343
| +20% | +$2.68M | 0.32% | 53 |
|
|
2013
Q2 | $12.8M | Buy |
+269,735
| New | +$13.7M | 0.3% | 57 |
|
Other funds holding AZN
Aperio Group's AZN Position: Q4 2020 in Review
Aperio Group reduced its AstraZeneca (AZN) stake by 5% in Q4 2020, selling an estimated $3.76M and leaving 679,527 shares worth $67.9M. The position accounts for 0.2% of the portfolio, ranked #79.
Aperio Group first reported a position in AZN in Q2 2013 and has held it in 30 quarters since. The position peaked at $78.4M in Q3 2020. 786 funds tracked by Wall St. Rank hold AZN as of Q4 2020.
- Aperio Group held 679,527 shares of AstraZeneca worth $67.9M as of Q4 2020.
- Aperio Group sold 35,482 AstraZeneca shares in Q4 2020, an estimated $3.76M.
- AstraZeneca made up 0.2% of Aperio Group's portfolio in Q4 2020, its #79 holding.
- Aperio Group first reported a position in AstraZeneca in Q2 2013 and has held it in 30 quarters since.
- Aperio Group's AstraZeneca position peaked at $78.4M in Q3 2020.
- 786 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.